| __timestamp | Cytokinetics, Incorporated | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 44426000 | 25434000 |
| Thursday, January 1, 2015 | 46398000 | 23783000 |
| Friday, January 1, 2016 | 59897000 | 29763000 |
| Sunday, January 1, 2017 | 90296000 | 12065000 |
| Monday, January 1, 2018 | 89135000 | 5508000 |
| Tuesday, January 1, 2019 | 86125000 | 75173000 |
| Wednesday, January 1, 2020 | 96951000 | 81497000 |
| Friday, January 1, 2021 | 159938000 | 85731000 |
| Saturday, January 1, 2022 | 240813000 | 63572000 |
| Sunday, January 1, 2023 | 330123000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding financial health is crucial. Cytokinetics, Incorporated and Mesoblast Limited, two prominent players, have shown contrasting trends in their cost of revenue from 2014 to 2023. Cytokinetics has experienced a staggering increase of over 640% in its cost of revenue, peaking in 2023. This growth reflects their aggressive expansion and investment in research and development. In contrast, Mesoblast's cost of revenue has remained relatively stable, with a modest increase of around 116% over the same period. This stability suggests a more conservative approach to financial management. Notably, 2024 data for Cytokinetics is missing, indicating potential reporting delays or strategic shifts. These insights provide a window into the financial strategies of these biotech firms, offering valuable lessons for investors and industry watchers alike.
Novo Nordisk A/S vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Cytokinetics, Incorporated
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost Insights: Breaking Down Zoetis Inc. and Cytokinetics, Incorporated's Expenses
Comparing Cost of Revenue Efficiency: Jazz Pharmaceuticals plc vs Cytokinetics, Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Comparing Cost of Revenue Efficiency: Cytokinetics, Incorporated vs Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Cytokinetics, Incorporated and CRISPR Therapeutics AG
Analyzing Cost of Revenue: Cytokinetics, Incorporated and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited